ADT-006

ADT-006 is a small molecule Ras inhibitor belonging to a novel class of indene derivatives. Developed by ADT Pharmaceuticals in collaboration with the University of South Alabama Mitchell Cancer Institute, it was identified as a back-up analog to the lead candidate DC070-547. ADT-006 is designed to selectively inhibit the growth of tumor cells harboring mutant or constitutively activated Ras proteins, including N-Ras and those activated by upstream tyrosine kinase receptor mutations like PDGFRα. The compound demonstrates high potency with IC50 values in the low nanomolar range and high selectivity (over 100-fold) for Ras-activated cells compared to wild-type cells. Its mechanism involves disrupting downstream Ras signaling, evidenced by the reduction of phosphorylated c-Raf and MEK levels, thereby inhibiting tumor cell proliferation and survival in Ras-driven cancers such as melanoma.